Adoptive cell transfer: A clinical path to effective cancer immunotherapy

Steven A. Rosenberg, Nicholas P. Restifo, James C. Yang, Richard A. Morgan, Mark E. Dudley

Research output: Contribution to journalArticle

Abstract

Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.

Original languageEnglish (US)
Pages (from-to)299-308
Number of pages10
JournalNature Reviews Cancer
Volume8
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Critical Pathways
Adoptive Transfer
Immunotherapy
Cell- and Tissue-Based Therapy
Neoplasms
Lymphocytes
Tumor-Infiltrating Lymphocytes
Melanoma
Lymphoma
Therapeutics
Tissue Donors
Transplants

ASJC Scopus subject areas

  • Cancer Research

Cite this

Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nature Reviews Cancer, 8(4), 299-308. https://doi.org/10.1038/nrc2355

Adoptive cell transfer : A clinical path to effective cancer immunotherapy. / Rosenberg, Steven A.; Restifo, Nicholas P.; Yang, James C.; Morgan, Richard A.; Dudley, Mark E.

In: Nature Reviews Cancer, Vol. 8, No. 4, 04.2008, p. 299-308.

Research output: Contribution to journalArticle

Rosenberg, SA, Restifo, NP, Yang, JC, Morgan, RA & Dudley, ME 2008, 'Adoptive cell transfer: A clinical path to effective cancer immunotherapy', Nature Reviews Cancer, vol. 8, no. 4, pp. 299-308. https://doi.org/10.1038/nrc2355
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nature Reviews Cancer. 2008 Apr;8(4):299-308. https://doi.org/10.1038/nrc2355
Rosenberg, Steven A. ; Restifo, Nicholas P. ; Yang, James C. ; Morgan, Richard A. ; Dudley, Mark E. / Adoptive cell transfer : A clinical path to effective cancer immunotherapy. In: Nature Reviews Cancer. 2008 ; Vol. 8, No. 4. pp. 299-308.
@article{00e190adbb8c49408b1eae9cbf700308,
title = "Adoptive cell transfer: A clinical path to effective cancer immunotherapy",
abstract = "Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50{\%} of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.",
author = "Rosenberg, {Steven A.} and Restifo, {Nicholas P.} and Yang, {James C.} and Morgan, {Richard A.} and Dudley, {Mark E.}",
year = "2008",
month = "4",
doi = "10.1038/nrc2355",
language = "English (US)",
volume = "8",
pages = "299--308",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Adoptive cell transfer

T2 - A clinical path to effective cancer immunotherapy

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

AU - Yang, James C.

AU - Morgan, Richard A.

AU - Dudley, Mark E.

PY - 2008/4

Y1 - 2008/4

N2 - Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.

AB - Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=41149097574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149097574&partnerID=8YFLogxK

U2 - 10.1038/nrc2355

DO - 10.1038/nrc2355

M3 - Article

C2 - 18354418

AN - SCOPUS:41149097574

VL - 8

SP - 299

EP - 308

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 4

ER -